Medicure 8/14/2024 Earnings Report

Medicure EPS Results

• Actual EPS: -$0.09
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Medicure Revenue Results

• Actual Revenue: $3.78 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Medicure Announcement Details

• Date: 8/14/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Medicure (OTCMKTS:MCUJF) is a Canadian specialty pharmaceutical company headquartered in Montreal, Quebec. The company focuses on the development, manufacture and commercialization of branded hospital and ambulatory care products, with a primary emphasis on therapies that support cardiovascular care. Medicure’s product portfolio includes prescription injectables and oral therapies designed to address acute care needs such as arrhythmia management, supportive care in surgical settings and hospital-based symptomatic relief.

In addition to its marketed products, Medicure maintains a pipeline of investigational assets targeting cardiovascular and perioperative complications. The company employs a hybrid model of in-house research and strategic partnerships to advance clinical candidates through regulatory pathways. Through these collaborations, Medicure seeks to bolster its core offerings and extend its reach into adjacent specialty therapeutic areas.

Founded in 2005 under the name Cardiome Pharmaceuticals, the company rebranded as Medicure in 2015 to reflect its broader focus on acute care treatment solutions. Over the years, Medicure has grown through a combination of internal development, licensing agreements and targeted acquisitions. These strategic moves have enabled the firm to expand its presence across North America and lay the groundwork for international distribution.

Under the leadership of Chief Executive Officer Angelo Jacovides and an experienced management team, Medicure has built a dedicated sales organization and forged key distribution partnerships. The company primarily serves hospitals, clinics and specialty pharmacies in Canada and the United States, leveraging contract manufacturing relationships and a network of commercial partners to ensure consistent supply and market access for its products.